[Clinical analysis of amphotericin B in the treatment of invasive fungal infections in 121 patients with hematologic diseases].
To observe the efficacy and safety of amphotericin B for treatment of invasive fungal infections (IFI) in patients with hematologic diseases. 121 patients were given amphotericin B 5 -50 mg/d for 5 - 101 d with a median of 19 d. The clinical efficacy rate was 67.3%, and fungal elimination rate 66.7%. The adverse events included rigor and fever, hypokalaemia, hepatic damage, nephrotoxicity, nausea and vomiting, phlebitis and teeter. Amphotericin B is still a high-efficiency drug in the treatment of IFI, although it has many side effects. With monitoring of hepatic and renal function, it is still a relatively safe and effective drug.